QbTest

Home Innovations QbTest

Next Previous

QbTest

5th March 2020

A test using objective measures to speed up ADHD diagnosis and improve treatment evaluation

QbTest is a CE-marked, FDA approved medical device that simultaneously measures attention, impulsivity and motor activity, a core requirement of the diagnostic criteria for ADHD. The individual patient’s performance is compared to an age and sex-matched control group in a clear visual report which aids diagnosis and treatment evaluation.

“For me, the QbTest was a really big eye opener because now there wasn’t just someone looking at me and noticing my struggles, there was a scientific foundation to it. I finally felt like someone was listening to me.”

Patient

“QbTest has finally provided us an evidence-based tool adding objecting measurement to ADHD assessment.”

Clinician

The challenge

Undiagnosed and/or untreated ADHD can have significant negative effects on the person’s academic performance and family interactions, and dramatically increases the likelihood of anxiety disorders, eating disorders, psychosis, and depression. Early diagnosis and timely interventions reduce such risks, yet in the UK the average delay from first clinic visit to diagnosis is 18 months, the worst in Europe.

The solution

The objective data from QbTest helps clinicians to rule out or diagnose ADHD more efficiently. Most patients receive a decision at their first appointment rather than making 2 or 3 visits over a prolonged period as per the current approach to diagnosis. ADHD clinics benefit from a 20% increase in capacity and greater confidence in decision making.

Impact*